GlassScriptPhysician profile
Gina Novak
NPI 1932249778
$6,976.71
in general payments reported to CMS, 2019-2025
38 companies · $1,798 in 2025
The $1,798 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $556 · 2022: $1,753 · 2023: $1,663 · 2024: $1,207 · 2025: $1,798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,667.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $928.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $787.24 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $556.20 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $504.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $477.85 | 2021-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $449.14 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $387.55 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $327.37 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $325.24 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $312.00 | 2022-2025 | Rexulti |
| Dexcom, INC. | $241.03 | 2024-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $163.28 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $153.20 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $136.05 | 2023 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.12 | 2021-2025 | Jardiance, Tradjenta |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Novak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.